felin
calicivirus
fcv
member
calicivirida
famili
genu
vesiviru
major
pathogen
cat
worldwid
viru
associ
vesicular
upper
respiratori
tract
diseas
especi
multicat
environ
shelter
coloni
catteri
fcv
detect
cat
fcv
infect
typic
caus
varieti
clinic
manifest
acut
respiratori
diseas
oral
ulcer
less
common
symptom
includ
pneumonia
acut
arthritislimp
syndrom
recent
highli
contagi
virul
strain
fcv
emerg
link
sever
diseas
fcvassoci
virul
system
diseas
vsd
high
mortal
rate
first
descript
fcvvsd
outbreak
occur
usa
europ
associ
genet
distinct
virul
fcv
strain
evolv
local
sever
diseas
mark
tropism
endotheli
epitheli
cell
skin
parenchym
organ
adult
cat
often
sever
affect
kitten
singlestrand
positivesens
fcv
rna
genom
kb
vpg
link
polyadenyl
includ
three
open
read
frame
orf
encod
nonstructur
protein
includ
proteas
polymeras
encod
major
capsid
protein
encod
minor
protein
compon
virion
wei
et
al
demonstr
activ
form
fcv
polymeras
bifunct
proteasepolymeras
propol
protein
fcv
show
high
level
genet
divers
due
lack
proofread
low
fidel
viral
polymeras
genom
recombin
differ
fcv
strain
coinfect
phylogenet
classif
fcv
strain
base
nucleotid
sequenc
demonstr
circul
singl
genogroup
gi
around
globe
except
japan
addit
circul
strain
belong
second
genogroup
gii
liveattenu
inactiv
vaccin
fcv
avail
year
use
differ
fcv
strain
monoval
bival
composit
current
vaccin
prevent
infect
viral
shed
develop
fcvvsd
reduc
even
prevent
clinic
symptom
moreov
specif
antivir
avail
fcv
infect
treatment
option
fcvvsd
limit
support
therapi
sever
studi
report
differ
antivir
strategi
fcv
one
earliest
attempt
use
phosphorodiamid
morpholino
oligom
pmo
treat
cat
three
fcv
outbreak
two
caus
fcvvsd
one
link
nonleth
fcv
pathotyp
show
promis
result
vs
cat
surviv
without
pmo
treatment
respect
mefloquin
humanapprov
pharmaceut
compound
use
prevent
treat
malaria
demonstr
antivir
activ
fcv
vitro
low
micromolar
concentr
half
maxim
effect
concentr
although
demonstr
poor
select
index
si
vitro
combin
treatment
mefloquin
recombin
felin
show
slight
improv
anoth
class
compound
test
fcv
includ
proteas
inhibitor
pi
synthet
pi
demonstr
antivir
activ
fcv
respect
effect
fcv
compar
rhinoviru
development
pi
rupintrivir
consid
broadspectrum
compound
show
addit
activ
felin
coronaviru
human
noroviru
recent
fexaramin
synthet
agonist
farnesoid
x
receptor
play
role
lipid
metabol
shown
effect
block
fcv
entri
use
vitro
assay
howev
singl
amino
acid
chang
domain
major
capsid
protein
abl
confer
resist
studi
combin
treatment
aforement
broadspectrum
pi
show
synergist
antivir
activ
synergi
log
volum
delay
emerg
viru
resist
viral
nonstructur
protein
proteas
rnadepend
rna
polymeras
rdrp
essenti
viral
replic
therefor
offer
attract
antivir
target
enzym
lack
host
homolog
minim
chanc
offtarget
effect
target
success
treatment
sever
virus
includ
human
immunodefici
viru
hiv
hepat
c
viru
hcv
use
purifi
recombin
propol
establish
two
vitro
assay
screen
new
fcv
antivir
compound
repres
nucleosid
analogu
na
nonnucleosid
inhibitor
nni
pi
broadspectrum
nitazoxanid
test
fcv
antivir
activ
use
vitro
enzym
cell
culturebas
method
identifi
two
antivir
agent
potenti
therapeut
option
fcv
infect
crandel
ree
felin
kidney
crfk
cell
american
type
cultur
collect
atcc
propag
eagl
minimum
essenti
medium
emem
atcc
supplement
vv
fetal
bovin
serum
sigmaaldrich
st
loui
mo
usa
uml
penicillin
thermo
fisher
waltham
usa
streptomycin
thermo
fisher
cell
grown
fcv
strain
genbank
access
number
purchas
atcc
thirteen
antivir
compound
select
base
report
vitro
antivir
effect
calicivirus
includ
nni
na
pi
broadspectrum
nitazoxanid
follow
compound
purchas
commerci
vendor
dalton
toronto
canada
beclabuvir
taizhou
crene
biotechnolog
zhejiang
china
ppnd
molport
riga
latvia
quercetagetin
chymostatin
famciclovir
sigmaaldrich
compound
school
pharmaci
pharmaceut
scienc
cardiff
univers
cardiff
uk
favipiravir
sofosbuvir
medchemexpress
monmouth
junction
middlesex
counti
nj
usa
carbosynth
berkshit
unit
kingdom
rupintrivir
vitro
technolog
melbourn
vic
australia
focu
bioscienc
brisban
qld
australia
nitazoxanid
sapphir
bioscienc
sydney
nsw
australia
stock
solut
compound
prepar
dimethyl
sulfoxid
dmso
aliquot
storag
propol
cd
fcv
urbana
genbank
access
commerci
synthes
poarq
vector
life
technolog
carlsbad
ca
usa
subclon
merck
millipor
burlington
usa
bamhi
sali
restrict
site
use
forward
revers
primer
produc
express
propol
contain
ctermin
histidin
tag
escherichia
coli
neb
ipswich
usa
grown
luriabertani
media
l
kanamycin
cultur
induc
mm
isopropyl
iptg
h
shake
bacteria
pellet
centrifug
chemic
lysi
pellet
perform
previous
describ
lysat
load
onto
column
biorad
hercul
ca
usa
purifi
imidazol
gradient
mm
use
akta
start
dualbuff
system
ge
healthcar
littl
chalfont
uk
equilibr
buffer
consist
mm
trishcl
mm
nacl
mm
imidazol
glycerol
vv
triton
vv
elut
buffer
compos
equilibr
buffer
mm
imidazol
purifi
protein
concentr
use
ultra
centrifug
filter
kda
cutoff
millipor
tokyo
japan
dialyz
three
buffer
decreas
nacl
concentr
mm
nacl
mm
trishcl
glycerol
vv
triton
vv
buffer
prepar
ph
protein
concentr
determin
use
bca
protein
assay
kit
life
technolog
crfk
cell
cellswel
seed
flatbottom
plate
incub
overnight
cell
monolay
treat
increas
concentr
compound
triplic
follow
h
incub
dmso
vehicl
vv
use
neg
control
cytotox
compound
measur
use
celltitreblu
viabil
assay
kit
promega
madison
wi
usa
accord
manufactur
instruct
fluoresc
measur
fluostar
optima
micropl
reader
bmg
labtech
ortenberg
germani
half
maxim
cytotox
concentr
determin
graphpad
prism
la
jolla
ca
usa
rdrp
activ
measur
monitor
format
doublestrand
rna
dsrna
singlestrand
rna
polycytidin
templat
poli
c
describ
previous
rdrp
activ
first
optim
increas
concentr
enzym
ng
per
reaction
vari
sodium
chlorid
nacl
concentr
mm
heatinactiv
rdrp
use
neg
control
accumul
dsrna
product
measur
use
fluoresc
dye
picogreen
life
technolog
reaction
perform
blackbottom
plate
contain
ng
fcv
propol
mm
trishcl
ph
mm
rgtp
ng
poli
c
rna
mm
mm
dithiothreitol
dtt
tween
vv
bovin
serum
albumin
bsa
vv
antivir
screen
fcv
propol
incub
test
compound
final
concentr
dmso
vehicl
dmso
min
addit
reaction
mixtur
incub
min
reaction
termin
mm
edta
follow
incub
picogreen
dsrna
quantit
graphpad
prism
use
plot
half
maxim
inhibitori
concentr
valu
amino
acid
aa
sequenc
cleavag
site
precursor
leader
capsid
lc
matur
capsid
protein
fcv
genom
synthes
fluorogen
substrat
peptid
genscript
piscataway
nj
usa
stock
solut
mm
prepar
dmso
proteas
assay
perform
plate
use
reaction
volum
contain
mm
hepe
ph
mm
dtt
mm
edta
glycerol
vv
ng
fcv
propol
fluorogen
substrat
initi
measur
determin
michaelismenten
constant
km
substrat
perform
use
increas
concentr
incub
h
influenc
increas
nacl
concentr
mm
proteas
activ
also
evalu
follow
determin
km
inhibit
assay
perform
substrat
either
pi
vehicl
control
dmso
incub
min
upon
cleavag
substrat
site
indic
quench
dabcyl
fluoresc
edan
group
abolish
fluoresc
gener
quantifi
excit
wavelength
nm
emiss
nm
polarstar
plate
reader
km
valu
determin
use
graphpad
prism
fcv
plaqu
reduct
assay
perform
previous
describ
crfk
monolay
cellswel
plate
infect
approxim
plaqu
form
unit
pfu
fcv
h
follow
addit
semisolid
agaros
overlay
contain
differ
concentr
compound
plate
incub
h
fix
stain
crystal
violet
plaqu
number
determin
drug
treatment
dmso
vehicl
control
defin
maxim
viral
infect
determin
whether
combin
nitazoxanid
synergist
antagonist
addit
effect
percentag
inhibit
fcv
infect
assess
doserespons
matrix
includ
four
concentr
nitazoxanid
rang
effect
drug
combin
assess
use
synergyfind
zerointeract
potenc
zip
model
use
gener
synergi
score
doserespons
matrix
synergist
antagonist
effect
shown
peak
horizont
plane
respect
least
two
independ
experi
triplic
dataset
perform
treatment
result
present
mean
standard
error
mean
sem
rtqpcr
use
evalu
reduct
fcv
rna
follow
antivir
treatment
briefli
crfk
cell
cellswel
plate
infect
fcv
multipl
infect
moi
h
media
replac
media
contain
drug
incub
h
fcv
viral
rna
extract
cell
supernat
use
qiamp
viral
rna
kit
qiagen
hilden
germani
follow
bp
amplicon
region
gener
use
univers
green
onestep
kit
biorad
describ
refer
standard
curv
gener
use
serial
dilut
plasmid
contain
end
fcv
genom
quantit
cycl
paramet
min
min
cycl
min
reaction
run
duplic
statist
calcul
perform
use
graphpad
prism
softwar
data
analyz
use
unpair
ttest
welch
correct
error
bar
depict
standard
error
mean
sem
level
signific
indic
ns
signific
p
p
p
p
success
express
fcv
propol
polyprotein
contain
ctermin
tag
e
coli
cell
control
promot
system
l
cultur
purifi
mg
propol
appear
expect
molecular
mass
kda
sdspage
presenc
histag
confirm
western
blot
confirm
rdrp
activ
propol
dual
protein
test
use
vitro
fluorescencebas
transcript
assay
dsrna
product
detect
picogreen
dye
fcv
transcript
activ
increas
increas
concentr
rdrp
ng
per
reaction
figur
furthermor
decreas
rdrp
activ
observ
increas
nacl
concentr
mm
figur
rdrp
activ
reduc
presenc
mm
nacl
complet
inhibit
mm
figur
six
nni
compound
quercetagetin
compound
ppnd
beclabuvir
test
fcv
rdrp
inhibit
use
picogreen
vitro
assay
tabl
fix
concentr
quercetagetin
ppnd
demonstr
signific
reduct
rdrp
activ
compar
mock
control
respect
figur
compound
slightli
reduc
fcv
rdrp
activ
compound
beclabuvir
show
minim
inhibitori
effect
dosedepend
inhibitori
respons
curv
gener
establish
valu
quercetagetin
ppnd
figur
c
nni
crfk
cell
determin
use
celltitreblu
viabil
assay
tabl
beclabuvir
demonstr
valu
compound
show
valu
whilst
nni
show
valu
tabl
addit
ppnd
quercetagetin
examin
use
fcv
plaqu
reduct
assay
inhibitori
activ
calcul
h
rel
mock
control
dmso
treatment
antivir
activ
observ
compound
plaqu
format
inhibit
tabl
previou
studi
demonstr
recombin
fcv
propol
exhibit
bifunct
activ
polymeras
proteas
vitro
therefor
also
establish
vitro
fret
fluorescencebas
assay
measur
fcv
proteas
activ
cleav
substrat
correspond
cleavag
site
demonstr
km
valu
figur
contrast
fcv
rdrp
proteas
activ
inhibit
increas
nacl
concentr
figur
develop
vitro
fret
assay
enabl
us
test
inhibitori
activ
three
previous
publish
pi
rupintrivir
chymostatin
exhibit
inhibitori
effect
fcv
proteas
vitro
inhibit
experi
demonstr
figur
tabl
five
na
compound
chosen
test
antivir
effect
fcv
cell
cultur
includ
famciclovir
sofosbuvir
na
test
previous
shown
antivir
effect
sever
viral
famili
calicivirus
herpesviru
paramyxovirus
orthomyxovirus
flavivirus
tabl
howev
antivir
efficaci
compound
fcv
infect
evalu
thu
far
addit
na
also
test
broadspectrum
antimicrobi
agent
nitazoxanid
whose
mechan
antivir
action
fulli
elucid
doserespons
compound
fcv
examin
use
plaqu
reduct
assay
compound
nitazoxanid
exhibit
doserespons
inhibit
fcv
plaqu
format
low
micromolar
concentr
respect
figur
b
compound
demonstr
valu
whilst
nitazoxanid
show
valu
tabl
therapeut
index
valu
ti
determin
respect
also
perform
rtqpcr
quantifi
fcv
rna
level
antivir
treatment
differ
concentr
nitazoxanid
shown
figur
decreas
dosedepend
fcv
rna
level
observ
h
treatment
compound
nitazoxanid
result
reduct
fcv
rna
level
whilst
reduc
rna
level
compar
mocktreat
cell
figur
sofosbuvir
show
modest
antivir
activ
inhibit
plaqu
format
famciclovir
exhibit
minim
fcv
antivir
activ
concentr
high
inhibit
plaqu
format
determin
synergist
effect
nitazoxanid
perform
plaqu
reduct
assay
sever
combin
concentr
figur
synergist
effect
shown
peak
horizont
plane
zip
synergi
score
vari
interact
compound
result
moder
synergist
effect
zip
synergi
score
maxim
synergi
concentr
nitazoxanid
respect
figur
fcv
common
pathogen
cat
usual
associ
acut
mild
selflimit
upper
respiratori
tract
diseas
howev
recent
highli
contagi
strain
viru
fcvvsd
report
usa
europ
three
state
australia
person
commun
http
auvirbaccomhomevetnewslettermainvetnewsletterresearchupdatefcvvsdhtml
lack
effect
vaccin
andor
antivir
treatment
fcv
infect
clear
unmet
need
identifi
effect
antivir
agent
improv
manag
control
fcv
infect
present
studi
evalu
differ
compound
four
differ
antivir
class
use
vitro
enzym
cell
culturebas
assay
previous
evalu
viru
identifi
na
broad
spectrum
antimicrobi
compound
nitazoxanid
potent
inhibitor
fcv
replic
figur
tabl
na
origin
design
use
hcv
promis
caliciviru
antivir
previous
test
human
murin
noroviru
similar
result
current
studi
use
vitro
assay
jin
et
al
show
triphosphoryl
inhibit
human
murin
noroviru
rdrp
activ
respect
studi
test
human
noroviru
replicon
cell
cultur
demonstr
relat
studi
also
shown
inhibit
murin
noroviru
human
noroviru
replicon
use
cell
culturebas
assay
recent
use
bcell
cultur
system
also
effect
inhibit
human
noroviru
therefor
result
consist
inhibitori
data
obtain
calicivirus
report
cite
studi
valopicitabin
prodrug
form
use
preclin
studi
treat
hcv
infect
howev
doserel
gastrointestin
advers
event
drug
place
clinic
hold
us
food
drug
administr
fda
although
promis
result
obtain
studi
concern
advers
sideeffect
may
limit
futur
clinic
use
treat
caliciviru
infect
nitazoxanid
broadspectrum
antimicrobi
compound
activ
anaerob
bacteria
protozoa
virus
fdaapprov
drug
licens
gastroenter
caus
parasit
cryptosporidium
parvum
giardia
intestinali
cell
cultur
nitazoxanid
evalu
sever
virus
show
inhibit
replic
rotaviru
adenoviru
canin
coronaviru
influenza
virus
among
other
present
studi
nitazoxanid
demonstr
fcv
within
rang
valu
found
test
virus
recent
drug
report
inhibit
gi
noroviru
replicon
replic
clear
replicon
host
cell
ineffect
murin
noroviru
nitazoxanid
commerci
latin
american
countri
india
treat
broad
spectrum
intestin
parasit
infect
current
clinic
trial
treat
noroviru
gastroenter
exampl
larg
random
doubleblind
placebocontrol
clinic
trial
conduct
use
nitazoxanid
treat
acut
gastroenter
mainli
caus
cryptosporidium
parvum
noroviru
rotaviru
hospit
aborigin
children
northern
territori
australia
also
publish
anecdot
evid
drug
work
noroviru
small
number
case
studi
veterinari
field
small
anim
cat
dog
receiv
nitazoxanid
treat
intestin
parasit
gookin
et
al
demonstr
success
use
nitazoxanid
elimin
shed
tritrichomona
foetu
caus
chronic
diarrhea
cat
anoth
studi
success
administr
nitazoxanid
treat
giardiasi
cryptosporidiosi
dog
demonstr
given
nitazoxanid
display
potent
inhibit
fcv
alreadi
use
clinic
set
felin
infect
data
illustr
nitazoxanid
could
repurpos
treatment
fcv
infect
howev
consid
narrow
vitro
therapeut
index
nitazoxanid
sideeffect
diarrhea
vomit
observ
cat
nitazoxanid
administr
concern
effect
dose
vivo
address
combin
antivir
compound
addit
synergist
effect
strategi
improv
drug
efficaci
reduc
antivir
toxic
limit
develop
viral
resist
demonstr
combin
nitazoxanid
cell
cultur
synergist
inhibitori
effect
fcv
averag
delta
score
figur
nitazoxanid
show
cytotox
crfk
cell
rel
low
concentr
synergist
effect
result
combin
could
use
limit
cytotox
effect
reduc
effect
concentr
nitazoxanid
overal
improv
efficaci
combin
treatment
present
studi
express
recombin
fcv
propol
high
yield
activ
protein
previou
studi
demonstr
fusion
protein
stabli
express
fcvinfect
cell
primari
activ
form
protein
maintain
proteas
polymeras
activ
previous
shown
wei
et
al
also
demonstr
high
concentr
nacl
mm
caus
reduct
rdrp
activ
figur
howev
effect
proteas
activ
observ
concentr
figur
six
nni
compound
test
current
studi
ppnd
quercetagetin
show
inhibit
fcv
rdrp
activ
valu
low
micromolar
rang
figur
tabl
previou
studi
ppnd
demonstr
potent
inhibit
rdrp
activ
virus
three
caliciviru
genera
noroviru
sapoviru
lagoviru
valu
howev
due
cell
permeabl
issu
limit
bioavail
antivir
efficaci
cell
cultur
ppnd
consid
potenti
antivir
drug
candid
current
studi
quercetagetin
display
polymeras
assay
inhibit
fcv
plaqu
format
therefor
suitabl
fcv
antivir
quercetagetin
natur
flavonoid
compound
first
report
potent
inhibitor
hcv
replic
vitro
compound
demonstr
potent
rdrp
inhibit
differ
hcv
genotyp
less
potent
cell
cultur
infecti
viru
quercetagetin
also
show
moder
inhibitori
activ
chikungunya
replicon
addit
polymeras
inhibit
assay
use
purifi
fcv
propol
also
describ
fret
proteas
assay
high
throughput
screen
fcv
proteas
inhibitor
viral
polymeras
proteas
play
crucial
role
viral
replic
cycl
attract
target
antivir
develop
sever
viral
pi
current
approv
develop
treat
pathogen
virus
hiv
hcv
sar
coronaviru
develop
felin
coronaviru
infect
felin
infecti
periton
use
fretbas
assay
test
three
previous
publish
pi
demonstr
moder
inhibit
proteas
figur
compound
previous
shown
potent
inhibit
proteas
noroviru
coronavirus
picornavirus
rang
howev
fcv
cellbas
assay
valu
obtain
similar
valu
obtain
studi
pi
rupintrivir
chymostatin
previous
demonstr
inhibit
human
noroviru
proteas
genogroup
ii
fretbas
assay
valu
respect
howev
inhibitori
effect
observ
either
pi
fcv
proteas
studi
among
na
test
famciclovir
use
treatment
felin
herpesviru
fhv
associ
clinic
diseas
drug
also
commerci
use
fcv
fhv
treatment
test
famciclovir
concentr
use
cell
cultur
plaqu
reduct
assay
antivir
effect
observ
data
show
compound
ineffect
inhibit
viru
replic
thu
poor
therapeut
option
treatment
fcv
infect
fcv
highli
infecti
respiratori
pathogen
cat
global
distribut
recent
fcvvsd
associ
highmort
outbreak
report
despit
avail
vaccin
high
divers
fcv
genom
play
key
role
vaccin
failur
also
basi
emerg
virul
strain
addit
current
approv
antivir
treat
diseas
report
establish
two
vitro
assay
allow
identif
novel
inhibitor
fcv
polymeras
proteas
present
find
implic
develop
fcv
antivir
provid
basi
design
select
drug
may
use
veterinari
clinic
use
vitro
assay
identifi
quercetagetin
ppnd
potent
rdrp
inhibitor
also
demonstr
moder
inhibit
proteas
activ
final
report
identif
two
compound
nitazoxanid
antivir
activ
fcv
cell
cultur
low
micromolar
concentr
potenti
combin
therapeut
util
treat
fcvinfect
cat
